Eddie K Abdalla1. 1. Department of Surgical Oncology-Unit 444, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Suite 12.2016, Houston, TX 77030, USA. eabdalla@mdanderson.org
Abstract
INTRODUCTION: The gold-standard treatment for colorectal liver metastases (CLM) is liver resection. Advances in staging, surgical technique, perioperative care and systemic chemotherapy have contributed to steady improvement in oncologic outcomes for patients following surgery in this subset of patients with stage IV colorectal cancer. The limits of resection continue to expand to include patients with more, larger and bilateral CLM, yet outcomes continue to improve with 5-year overall survival exceeding 50% following resection. Chemotherapy is an important element of treatment for patients with CLM, and chemotherapy can be combined safely with surgery to improve outcomes further. METHODS: Tailored approaches to patients include major (anatomic) resection, minor (wedge) resection, liver volumetry, and preoperative enhancement of the volume and function of the planned future remnant liver using portal vein embolization. RESULTS: Assessment of response to chemotherapy, analysis of liver remnant volume changes following portal vein embolization, and consideration of the surgical recovery following multistage surgical resection of bilateral CLM enable remarkable survival even among properly selected patients with extensive disease. CONCLUSIONS: Until laboratory, pathologic, biologic, or genetic studies can define which patients will benefit most from surgical and other treatments, careful application of proven diagnostic and therapeutic approaches to patients with advanced disease will continue to allow surgeons to direct tailored, patient-centered treatment as part of a multidisciplinary team.
INTRODUCTION: The gold-standard treatment for colorectal liver metastases (CLM) is liver resection. Advances in staging, surgical technique, perioperative care and systemic chemotherapy have contributed to steady improvement in oncologic outcomes for patients following surgery in this subset of patients with stage IV colorectal cancer. The limits of resection continue to expand to include patients with more, larger and bilateral CLM, yet outcomes continue to improve with 5-year overall survival exceeding 50% following resection. Chemotherapy is an important element of treatment for patients with CLM, and chemotherapy can be combined safely with surgery to improve outcomes further. METHODS: Tailored approaches to patients include major (anatomic) resection, minor (wedge) resection, liver volumetry, and preoperative enhancement of the volume and function of the planned future remnant liver using portal vein embolization. RESULTS: Assessment of response to chemotherapy, analysis of liver remnant volume changes following portal vein embolization, and consideration of the surgical recovery following multistage surgical resection of bilateral CLM enable remarkable survival even among properly selected patients with extensive disease. CONCLUSIONS: Until laboratory, pathologic, biologic, or genetic studies can define which patients will benefit most from surgical and other treatments, careful application of proven diagnostic and therapeutic approaches to patients with advanced disease will continue to allow surgeons to direct tailored, patient-centered treatment as part of a multidisciplinary team.
Authors: Eddie K Abdalla; René Adam; Anton J Bilchik; Daniel Jaeck; Jean-Nicolas Vauthey; David Mahvi Journal: Ann Surg Oncol Date: 2006-09-06 Impact factor: 5.344
Authors: Timothy M Pawlik; Charles R Scoggins; Daria Zorzi; Eddie K Abdalla; Axel Andres; Cathy Eng; Steven A Curley; Evelyne M Loyer; Andrea Muratore; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Antoine Brouquet; Melinda M Mortenson; Jean-Nicolas Vauthey; Miguel A Rodriguez-Bigas; Michael J Overman; George J Chang; Scott Kopetz; Christopher Garrett; Steven A Curley; Eddie K Abdalla Journal: J Am Coll Surg Date: 2010-06 Impact factor: 6.113
Authors: George A Poultsides; Elliot L Servais; Leonard B Saltz; Sujata Patil; Nancy E Kemeny; Jose G Guillem; Martin Weiser; Larissa K F Temple; W Douglas Wong; Phillip B Paty Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Daria Zorzi; Yun Shin Chun; David C Madoff; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: Ann Surg Oncol Date: 2008-07-18 Impact factor: 5.344
Authors: Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla Journal: J Gastrointest Surg Date: 2007-09-11 Impact factor: 3.452
Authors: Daria Zorzi; John T Mullen; Eddie K Abdalla; Timothy M Pawlik; Axel Andres; Andrea Muratore; Steven A Curley; Gilles Mentha; Lorenzo Capussotti; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2006-01 Impact factor: 3.267
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: C S van Kessel; M S van Leeuwen; R van Hillegersberg; I H M Borel Rinkes; M A A J van den Bosch; I Q Molenaar Journal: J Gastrointest Surg Date: 2013-04-25 Impact factor: 3.452
Authors: Y Dittmar; A Altendorf-Hofmann; S Schüle; M Ardelt; O Dirsch; I B Runnebaum; U Settmacher Journal: J Cancer Res Clin Oncol Date: 2013-05-04 Impact factor: 4.553
Authors: Ricky Harminder Bhogal; James Hodson; Simon Roderick Bramhall; John Isaac; Ravi Marudanayagam; Darius Feroze Mirza; Paolo Muiesan; Robert Peter Sutcliffe Journal: World J Surg Oncol Date: 2015-04-01 Impact factor: 2.754